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A B S T R A C T  
Objective: To identify gene mutations known to cause thalassemia major and intermedia amongst patients coming to 
thalassemia Centre of Pakistan Institute of Medical Sciences(PIMS). 
Patients and Methods: Hundred transfusion dependent thalassemia patients were recruited from PIMS. Genome DNA 
was isolated by using phenol-chloroform method. Allele specific PCR was performed by using primers specific for twelve 
known disease causing mutations, prevalent in Pakistan. The PCR product was run on 6% polyacrylamide gel 
electrophoresis and visualized by silver staining technique. Results were recorded and data were entered and analyzed 
using SPSS version 16. 
Results: Total Number of patients included in the study was 100, among them 46% were males and 54% were females. 
Parenteral consanguinity was seen in 95% cases. Most common homozygous mutations were Fr 8-9 [23(28.7%)], 
followed by IVSI-5 [17(21.3%)] cases. Compound heterozygous mutations were seen in 20% cases, among them the 
most common was Fr 8-9/IVS1-5 (5/20 cases), and Fr 8-9/del 619 (3/20 cases). Analysis of type of mutation in different 
ethnic groups showed that Fr 8-9 was the most common mutation in Punjabis and Pathans seen in 14/63 and 6/28 
cases respectively, followed by IVS1-5 seen in 11/63 and 5/28 cases respectively.  The most common mutation in 
Thalassemia major was Fr 8-9 seen in 22 (25%) cases followed by IVS1-5 seen in 15 (17%) cases and Fr 41-42 seen in 
10 (11.4%) cases. The number of patients of Thalassemia Intermedia was low in this study (n=12), however among 
these the commonest mutations were Cap +1, Fr 8-9, IVS1-5 and del 619, presenting as homozygous or compound 
heterozygous mutations. 
Conclusion: Molecular characterization of Thalassemia major and intermedia patients is very essential so that we can 
set trigger of hemoglobin level accordingly before putting them on regular transfusion. Less frequent transfusion, iron 
chelation and HU therapy will significantly reduce serum ferritin, liver and spleen size of this group of patients and thus 
significantly improve their quality of life. 
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I n t r o d u c t i o n  
 
Beta Thalassaemia is one of the most common 
monogenic disorders in Pakistan with career rate of 5-
8%.1 Every year, almost 5000 new children are born with 
thalassemia major.2 Among haemoglobin disorders, β 
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thalassemia is one of the most common causes of 
morbidity and mortality worldwide.3 Beta thalassemia is 
inherited in autosomal recessive pattern and almost 300 
mutations have been identified in α or β globin gene 
which impairs transcription, mRNA processing or its 
translation.4 With exception of a few deletions, vast 
majority of β thalassaemias are caused by point 
mutations within the gene or its immediate flanking 
sequences.5 Depending on whether thalassemia is 
heterozygous or homozygous, the phenotypic form varies 
from asymptomatic state known as thalassemia minor to a 
transfusion dependent form known as thalassemia major. 
This clinical variability mainly depends on β-globin 
genotype. About 20 mutations account for 90 percent of 
β-globin genes effects in the world and it is noted that 
each ethnic population has its own unique set of most 
frequent mutations.6 βl0/β0 is the severest-manifesting 
genotype, in which no β-chain production occurs; in β+/β 
+ or βl0/β+ genotype, β-chains are produced in small 
quantities, allowing a small amount of HbA production. A 
small percentage of patients have silent β thalassemia; 
these patients have β+ thalassaemia in which the deficit 
in β globin chains production is minimal. Such individuals 
present with normal HbA2 levels on haemoglobin 
electrophoresis, making their identification difficult with 
conventional methods, thus making genetic analysis 
mandatory for detection of thalassemia.2,7 Further, a co-
inheritance of α-thalassemia or various 
hemoglobinopathies with β-thalassemia may manifest as 
thalassemia intermedia, in which anemia is moderate, and 
the patient is usually not transfusion dependent, except in 
stress like various types of infections.8   
Epidemiological data about prevalence and distribution of 
mutations plays a very crucial role in development of 
effective disease management strategies. Previous 
studies conducted in different ethnic groups of Pakistan 
showed prevalence of six mutations, Fr 8-9 (+G), IVSI-5 
(G-C), Fr 41-42 (–TTCT), Del 619 bp, Cd 15 (G-A) and 
IVSI-1 (G-T). Similarly, Thalassemia Intermedia 
(TI)encompasses a wide clinical spectrum of beta 
thalassemia phenotype and various genetic factors affect 
the severity of disease and response to treatment, 
particularly in TI. This study was aimed to identify disease 
causing mutations in selected Pakistani patients. 
P a t i e n t s  a n d  M e t h o d s  
The study was designed to identify underlying beta globin 
gene mutation in patients with beta thalassemia major. 
The study protocol was approved by the institutional 
review board and informed written consent was obtained 
before sample collection from patients. A total of 100 
transfusion dependent beta thalassemia cases were 
recruited   from Pakistan institute of medical sciences, 
Islamabad. Clinical details of the patients were obtained 
and blood samples of the selected patients were collected 
in EDTA vacutainer tubes. Genomic DNA was isolated by 
using Phenol-Chloroform method.9 The isolated DNA was 
then amplified to detect 12 previously known mutations in 
Pakistani subjects [IVSI-5 (G-C), Fr 8-9 (+G), IVSI-1 (G-
T), Fr 41-42 (–TTCT), Del 619 bp, Cd 15 (G-A), Cd 5 (–
CT), Cd30 (G-C), Cd 30 (G-A), Fr 16 (–C), IVSII-1 (G-A), 
Cap +1 (A-C)] by using mutation specific primers.1 
Multiplex ampliﬁcation refractory mutation system (ARMS) 
PCR was performed in three separate reaction mixtures. 
The first reaction mixture contained primers specific for 
amplification of Fr 8-9 (+G), Fr 41-42 (-TTCT), IVSI-5 (G-
C), IVSI-1 (G-T) and Del 619. The second reaction 
mixture contained primers specific for Cd 5 (-CT), Fr 16(-
C), IVSI-1 (G-T), Cd30 (G-C), Cd 30 (G-A), and IVSII-1 
(G-A) while the third reaction mixture contained primers 
specific for Cd 15 (G-A) and Cap +1 (A-C). 
PCR reaction mixture was prepared by using 5 pmol of 
each primers, 0.2 units of Taq Polymerase (company 
name), 10 mM of each dNTP (company name), 25 mmol 
MgCl2, 100 mM Tris-HCl and 500 mM KCl (pH 8.3) and 
30-50 ng of DNA. The PCR amplification process 
consisted initial denaturation at 94oC for 10 minutes 
followed by of 25 cycles of denaturation at 94oC for one 
minute, primer annealing at 65oC for one minute, and 
DNA extension reaction at 72oC for 1.5 minute. Final 
extension was done at 72oC for 3 minutes. The amplified 
product was resolved by using 6% mini polyacrylamide 
gel at 180 V for 20 minutes. After electrophoresis, gels 
were stained by dipping it in 0.1% silver nitrate solution for 
15 mins and later treating with a freshly prepared solution 
of 1.5% NaOH and 0.15% formaldehyde until the bands 
appear. Gels were interpreted and images were recorded. 
If a single mutation was obtained, a second PCR was 
performed with a set of primers specific for the normal  
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allele of the respective mutation to detect the presence of 
wild type sequence. If the normal allele was ampliﬁed, the 
patient was considered heterozygous carrier. However, if 
the normal counterpart was not detected, the patient was 
considered homozygous recessive the respective 
mutation.  
R e s u l t s  
Total Number of patients included in the study was 100, 
among them 46% were males and 54% were females. 
Mean Age (in months) at diagnosis was 13.48±11.65 (3-
66 Months) and median Age (in months) at diagnosis was 
8 (2-156 months). Mean age at diagnosis of Thalassemia 
Major was 8.09±3.30 months and mean age at diagnosis 
of Thalassemia Intermedia was 44.50±39.5. As shown in 
table 1, the most common ethnic groups were Punjabis 
(63%) and Pathans (29%). Parenteral consanguinity was 
seen in 95% cases; out of these 92% being 1st cousins. 
 
Table 1: Demographic characteristics of patients 
 n (%) 
Gender Male 46 (46 ) 
 Female 54 (54) 
Ethnicity Hinko 1 (1) 
 Punjabi 63(63) 
 Potohari 1 (1) 
 Pathan 29 (29) 
 Kashmiri 4 (4) 
 Other 3 (3) 
Parental 
Consanguinity  
Yes 95 (95) 
 No 5 (5) 
Relationship 
between parents 
1st cousins 97 (97) 
 More distant 
relationship 
3 (3) 
 
Homozygous mutations were seen in 76% cases; the 
most common homozygous mutations were Fr 8-9 
[23(28.7%)], followed by IVSI-5 [17(21.3%)] cases, table 
2. In 4% cases no mutation was found. Compound 
heterozygous mutations were seen in 20% cases, among 
them the most common was Fr 8-9/IVS1-5 (5/20 cases), 
and Fr 8-9/del 619 (3/20 cases) Table 3. 
 
 
Table 2: Frequency of homozygous mutations 
(n=80) 
S.No Mutation Frequency (%) 
1 Fr 8-9 23 (28.7) 
2 Fr 41-42 10 (12.5) 
3 Fr 16 6 (7.5%) 
4 Del 619 10 (12.5) 
5 Cd 30 4 (5%) 
6 Cap +1 2 (2.5) 
7 IVSI-1 3 (3.8) 
8 IVSII-1 1 (1.2) 
9 IVSI-5 17 (21.3) 
10 No mutation 4 (5) 
 
Table 3: Compound heterozygous mutations in 
beta-globin gene (n=20) 
S. No Mutation Frequency 
1 Cap+1/IVSII-1 1 (5) 
2 Cd 30/Fr 16 1 (5) 
4 Fr 8-9/ Fr 16 1 (5) 
5 Fr 8-9/ Fr 41-42 1 (5) 
6 Fr 8-9/Cd 5 1 (5) 
7 Fr 8-9/del 619 3 (15) 
8 Fr 8-9/IVSI-5 5 (25) 
10 Fr 8-9/Cap+1 2 (10) 
11 Fr 41-42/ IVSI-5 2 (10) 
12 Fr 41-42/ IVSI-1 1 (5) 
13 IVSI-5/ IVSII-1 1 (5) 
14 IVSII-1/ Cd 5 1 (5) 
 
Analysis of type of mutation in different ethnic groups 
showed that Fr 8-9 was the most common mutation in 
Punjabis and Pathans seen in 14/63 and 6/28 cases 
respectively, followed by IVS1-5 seen 11/63 and 5/28 
cases respectively (table 4). As shown in the table 5, the 
most common mutation in Thalassemia major was Fr 8-9 
seen in 22 (25%) cases followed by IVS1-5 seen in 15 
(17%) cases and Fr 41-42 seen in 10 (11.4%) cases. The 
number of patients of Thalassemia Intermedia was low in 
this study (n=12), however among these the commonest 
mutations were Cap +1, Fr 8-9, IVS1-5 and del 619, 
presenting as homozygous or compound heterozygous 
mutations. 
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D i s c u s s i o n  
Beta thalassaemia is a major health burden in Pakistan. 
Despite preventive measures, around 5000 children with 
transfusion dependent TI or TM are annually added to the 
registry. No permanent cure is available, except stem cell 
transplantation, which is unaffordable due to high cost. 
The majority of patients with transfusion-dependent 
thalassaemia have no choice but to have regular blood 
transfusions and iron chelation therapy. Haemoglobin F 
augmentation through HU therapy is another ray of hope 
to avoid blood transfusions and associated complications. 
It is thus important to predict phenotype from genotype 
as; different patients have different clinical severity and 
response to treatment to HU depending upon their genetic 
makeup. The present study showed that mean age at 
diagnosis in Thalassemia major patients was 8 months 
and those of Thalassemia Intermedia was more than 3 
years. Consanguinity was seen in 95% cases  
majority  being 1st cousins. In a study conducted by Khan 
et al in district Bannu to find consanguinity ratio in Beta - 
 
Thalassemia major patients, consanguinity was reported 
in 74% parents while 26% were unrelated.10 Regarding 
genetic mutations, Fr 8-9 and IVS1-5 were the most 
common mutations seen in different studies (Table 6). 
Similar finding are reported by Ali et al.11 Another study 
conducted by Usman et al in 2009 reported that IVS-1-5 
(G→C), Fr 8/9 (+G), Fr 41/42 (-TTCT), IVS-1-1(G→T) 
and Del 619 comprised 90 % of Beta Thalassemia 
mutations in Pakistani population.12 In a study conducted 
by Tariq et al, it was reported that out of the 13 mutations 
tested, three mutations accounted for 71% of the total, 
and these included, IVS1-5, Fr 8-9 and del 619 bp.13  Our 
study shows similar result. 
The population of Pakistan is mainly divided into Punjabis 
and Pathans in the North and Balochis and Sindhis in 
South. Apart from these, there are other groups such as 
Urdu speaking, Memons, Gujrati, Saraiki, Kashmisri, 
Pothohari etc. Frequency of mutations may be different in 
different ethnic groups. Khan et al reported that four most 
common mutations, IVSI-5 (G+C) (37.7%), codons 8/9 
Table 4: Types of mutations in different ethnic groups (n=100) 
 Hinko 
(n=1) 
Kashmiri 
(n=4) 
Pathan 
(n=28) 
Pothohari 
(n=1) 
Punjabi 
(63) 
Others 
(n=3) 
Fr 8-9 (n=23) - 2 6 1 14 - 
IVSI-5 (n=17) - 1 5 - 11 - 
del 619 (n=10) - 1 2 - 6 1 
Fr 41-42 (n=10) 1 - 4 - 5 - 
Fr-16 (n=6) - - 2 - 4 - 
Cd-30 (n=4) - - 2 - 2 - 
IVSI –1 (n=3) - - - - 2 1 
Cap +1 (n=2) - - 1 - 1 - 
IVSII-1 (n=1) - - - - 1 - 
Cap +1 /IVS11-1 
(n=1) 
- - 1 - - - 
Cd-30/Fr 16 (n=1) - - - - 1 - 
Fr 16 / Fr 8-9 (n=1) - - 1 - - - 
Fr 41-42 / Fr 8-9 (n=1) - - - - 1 - 
Fr 41-42 / IVSI-1 (n=1) - - - - 1 - 
Fr 41-42/IVSI-5 (n=2) - - 1 - 1 - 
Fr 8-9 / IVSI-5 (n=5) - - 1 - 4 - 
Fr 8-9 / del619 (n=3) - - - - 3 - 
Fr 8-9 /Cd-5 (n=1) - - 1 - - - 
Fr 8-9/ cap+1 (n=2) - - - - 1 1 
IVSI-5 /IVSII-1 (n=1) - - - - 1 - 
IVSII - 1 /Cd-5 (n=1) - - - - 1 - 
No Mutation (n=4) - - 1 - 3 - 
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(+G) (21.1%), the 619 bp deletion (12.4%), and IVSI-1 
(G+T) (9.5%), collectively comprise 80.7 % of mutations. 
They also reported that in the four provinces of Pakistan, 
IVSI-5 (G-C) mutation was more prevalent in Sindh and 
Balochistan, which share borders with India in the south 
and Iran in the southwest, while Fr 8-9 mutation was more 
common in the Punjab and the Khyber Pakhtoon Khawa 
Province, sharing borders with India in the Northeast and 
Afghanistan, respectively. They further highlighted that 
619 bp deletion was high (46%) in Gujratis and Memons 
residing in the Province of Sindh, neighboring the Indian 
Gujrat.14  
Table 5: Different types of mutations in 
Thalassemia Major and Intermedia patients(n 100) 
Mutations Thalassemia 
Major 
(n=88) 
Thalassemia 
Intermedia 
(n=12) 
Fr 8-9  (n=23) 22 1 
IVSI-5  (n=17)  15 2 
Fr 41-42  (n=10) 10 0 
del 619  (n=10) 8 2 
Fr-16  (n=6) 5 1 
Cd-30  (n=4) 4 0 
Fr 8-9 / del619  
(n=3) 
3 0 
Fr 8-9/IVSI-5  (n=5) 4 1 
IVSI – 1  (n=3) 2 1 
Fr 41-42/IVSI-5  
(n=2) 
2 0 
Cap + 1  (n=2) 2 0 
Cap + 1 / IVS11-1 
(n=1) 
0 1 
Cd-30/Fr 1  (n=1) 1 0 
Fr 16 / Fr 8-9  (n=1) 0 1 
Fr 41-42 / Fr 8-9  
(n=1) 
1 0 
Fr 41-42 / IVSI-1  
(n=1) 
1 0 
Fr 8-9 /Cd-5  (n=1) 1 0 
Fr 8-9/ cap+1  (n=2) 1 1 
IVSI-5 /IVSII-1  
(n=1) 
1 0 
IVSII - 1 /Cd-5  
(n=1) 
0 1 
IVSII-1   (n=1) 1 0 
Uncharacterized   
(n=4) 
4 0 
We found that Fr 8-9 was the most common mutation in 
Punjabis and Pathans followed by IVS 1-5. Ansari et al 
found that IVS1-5 was the most common mutation in 
Sindis, Blochis and Punjabis followed by Fr 8-9, whereas 
in Pathans Fr 8-9 was the commonest mutation followed 
by IVS1-5. 6 Similarly a study done by Akhtar et al to look 
for spectrum of  Beta thalassaemia mutations, reported  
predominance of FR 8-9 and IVSI-5 mutation in Punjabis 
and Pathans and CAP+1 as the commonest silent 
mutation.15 Same results have been observed for the 
Indian population as shown by the studies of Garewal G 
et al 16 and Varawalla NY et al 17.  
A study done by Baig et al to look for spectrum of beta-
thalassemia mutations in various regions of Punjab and 
Islamabad, reported that distribution of mutations in 
Punjab and the Capital territory was different from the 
overall pattern in Pakistan. They reported that three most 
common mutations; IVS-I-5 (G-C), codons 8/9, (+G) and 
codons 41/42 (-TTCT) constitute 86.8% of mutations. 
They further highlighted that IVS-I-5 was the most 
common mutation seen in 39.0% cases in all regions 
being highest in South Punjab (45.0%) i.e. D.G. Khan, 
Bahawalpur and Multan region, whereas codons 8/9 (+G) 
was the second most frequent mutation seen in 37.3% 
cases but was number one in the patients from 
Rawalpindi-Islamabad (34.9%). The deletion of TTCT 
between codons 41 and 42 of the beta-globin gene was 
the third most common mutation (10.6%) in their study. 
The rest of 14 beta thalassemia mutations were less 
common or rare and comprised only13.9 %.18 
Taking into consideration all the studies, the primary and 
secondary panels of primers of ethnic specific mutations 
can be devised. With reference to uncharacterized 
mutation, samples should be sent for genetic sequencing. 
A study conducted to analyze spectrum of β-thalassaemia 
mutations in India, Pakistan and Sri Lanka showed that 
IVSI-5 (G>C) was the most common β-thalassaemia 
mutation in all three countries, with different frequencies, 
i.e. 64.6% in Sri Lanka to 56.3% in India and 36.5% in 
Pakistan. The second most common mutation in India 
was a 619-bp deletion (9.2%), in Pakistan Fr 8-9 (31.2%), 
and in Sri Lanka IVS I-1 (G>A) (17.5%). In Pakistan, the 
frequency of Fr 8-9 (31.2%) was close to that of IVSI-5 
(G>C) (36.5%). This study also highlighted the frequency 
of mutations in different ethnic groups. 
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They reported that data from Pakistan showed a 
significant variability in the distribution of β-thalassaemia 
mutations in four provinces. It was reported that,  unlike 
any region of India, IVSI-5 (G>C) was the most common 
mutation in Sindh and Baluchistan, whereas, Fr 8/9 (+G) 
was the most common β-thalassaemia allele in both 
Punjab (38.6%) and Khyber Pakhtunkwha (47.7%), 
though it was only the fourth most common allele across 
India, suggesting that its origin may have been effected 
by mutations of adjoining regions of neighboring 
countries, such as Afghanistan.19 These findings are 
comparable to our study, where Fr 8-9 was most common 
mutation observed in Punjabis and Pathans. In our study, 
Cap + 1 mutation was seen in 5 cases (2 homozygous 
and 3 heterozygous cases). Karim et al reported Cap+1 
mutation in 5% in targeted thalassemic families (having 
patients with beta-thalassemia intermedia) while its 
frequency was observed 2% in total thalassemic genes in 
Pakistani population.20 
In our study, number of patients of Thalassemia 
intermedia was low, i.e. 12 patients and among them 
IVSI-5 and del 619 were most common mutations. In a 
study conducted by J Khan et al, IVS-I-5 (50.0%) was the 
most frequent mutation in Beta-TI followed by Fr 8-9 
(9.5%), codons 41/42 (3.4%), and Cap + 1 (3.1%). 
Homozygous Beta + allele, co-inheritance of alpha gene 
deletion and co-inheritance of Xmnl1 polymorphism all  
contribute to reduced severity of disease in Thalassemia  
intermedia.21 Response to HU therapy has also been 
reported as more favorable in the presence of XmnI1 
polymorphism.11 However, limitation of our study was that 
we did not evaluate for Xmnl1 polymorphism and alpha 
gene deletion. We also observed, though some patients 
presented after two years but they were started regular 
transfusions without knowing their genotype (Thalassemia 
major or Intermedia) and were treated as Thalassemia 
major cases. It is thus suggested to evaluate the genetic 
mutation of all cases of beta thalassemia major and 
intermedia first, and put them on transfusion therapy 
accordingly. As TI patients, not only require less frequent 
transfusions, they can withstand low hemoglobin level as 
compared to TM patients. And respond better to HU than 
Thalassemia major patients. If we know the genotype of 
these patients of Thalassemia intermedia, and they are 
managed with less transfusions, HU therapy and good 
iron chelation we can significantly improve their quality of 
life. 
C o n c l u s i o n  
This study adds to the pre-existing data in Pakistan. We 
can device primary and secondary panels of primers of 
genetic mutations for a specific population. Molecular 
characterization of Thalassemia major and intermedia 
patients is very essential so that we can set a trigger 
hemoglobin accordingly before putting them on regular 
transfusion. Less frequent transfusion, iron chelation and  
Table 6: Frequency of mutations seen in different studies from Pakistan 
Type of mutation Khan et al 
1998 (14) 
Usman et al  
2009 (120 
Akhtar et al 
2012 (15) 
Ali et al 
2015 (11) 
Baig et al 
2006 (18) 
 
Ansari et al 
2011 (6) 
Present Study 
2017 
IVS 1-5  37.7 44.4 24.5 36 38.9 40.89 21% 
Fr 8-9 21.1 14.6 35.5 40 37.3 15.7 29.5% 
Fr 41-42 - 17.5 14.8 4 10.6  12% 
Fr 16 -  1.6 2   7% 
Cd5 3.1  6.6 8 1.3 2.16 1% 
Cd15 3.1  07 8 1.8  - 
Cd30 -  3.9 1 0.7 8.02 4.5% 
IVS II-1 0.7   1 0.8  2.5% 
619 bp del 12.4 0.6 1.6  1.9 11.11 6.5% 
IVS 1-1 G-T 9.5 7.5 1.9  1.9 8.17 3.5% 
Cap+ 1 1.2  1.7    3.5% 
Uncharacterized   0.8    2% 
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HU therapy will significantly reduce serum ferritin, liver 
and spleen size of this group of patients and thus 
significantly improve their quality of life. 
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